Bioventus Inc. (NYSE:BVS) SVP Sells $44,632.20 in Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Bioventus Stock Down 3.6 %

BVS stock traded down $0.37 during midday trading on Thursday, reaching $9.95. 322,403 shares of the company’s stock traded hands, compared to its average volume of 272,552. The company has a market cap of $807.44 million, a price-to-earnings ratio of -16.31 and a beta of 0.85. The firm’s fifty day moving average price is $10.37 and its 200-day moving average price is $10.83. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38.

Institutional Trading of Bioventus

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Bioventus by 38.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after acquiring an additional 109,359 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Bioventus in the 3rd quarter worth $4,515,000. Point72 Asset Management L.P. bought a new stake in shares of Bioventus in the 3rd quarter worth $788,000. JPMorgan Chase & Co. grew its stake in shares of Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after acquiring an additional 176,442 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after acquiring an additional 189,216 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BVS. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group boosted their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.